Central antinociceptive effects of cannabinoids have been well documented. However, relatively little is known about the periphe effects of the cannabinoids on inflammation. In the present study, we evaluated the effects of peripherally administered cannabinoids three indices of inflammation: carrageenan-induced thermal hyperalgesia, carrageenan-induced edema, and capsaicin-induced plas extravasation. In addition, we determined the effect of cannabinoids on capsaicin-evoked neuropeptide release from isolated rat hindp skin. Our results indicate that cannabinoids produce antihyperalgesia via interaction with a peripheral CB 1 receptor. Peripheral, but systemic, administration of 0.01 ng anandamide inhibited the induction of hyperalgesia. Peripheral administration of anandamide a attenuated hyperalgesia after its development via interaction with the CB 1 cannabinoid receptor subtype as indicated by its reversal with CB 1 receptor antagonist SR 141716A. Additionally, peripheral, but not systemic, administration of 0.01 ng anandamide inhibited edem Peripherally administered cannabinoids also interacted with CB 1 receptors to inhibit capsaicin-evoked plasma extravasation into hindpaw. One potential mechanism for the anti-inflammatory actions of the cannabinoids is the inhibition of neurosecretion from peripheral terminals of nociceptive primary afferent fibers. This hypothesis is supported by the finding that anandamide inhibited capsaic evoked release of calcitonin gene-related peptide from isolated hindpaw skin. Collectively, these results indicate that cannabinoids redu inflammation via interaction with a peripheral CB 1 receptor. A potential mechanism for this effect is the inhibition of neurosecretion fr capsaicin-sensitive primary afferent fibers.
Introduction
Reports of marijuana-induced analgesia date back millennia (Hall et al., 1994) . However, studying the antinociceptive and antihyperalgesic roles of cannabinoids has proved difficult because of the lack of identified receptors and selective agonists and antagonists. Recently, the CB 1 and CB 2 receptor subtypes were cloned and determined to be members of the G protein-coupled receptor family (Matsuda et al., 1990; Munro et al., 1993) . Additionally, in the l few decades selective synthetic cannabinoids have be developed and endogenous cannabinoids discovered (Le berger and Rowe, 1975; Johnson et al., 1981; D'Ambra al., 1992; Devane et al., 1992; Hanus et al., 1993; Mecho lam et al., 1995; Sugiura et al., 1995) . Such developmen have resulted in the determination that activation of cent cannabinoid receptors produces antinociception (Yak 1981; Herkenham et al., 1991; Lichtman and Mart 1991; Martin et al., 1993 Martin et al., , 1995 Martin et al., , 1996 Smith et al., 199 Hohmann et al., 1995; Lichtman et al., 1996; Hohmann a Herkenham, 1997; Richardson et al., 1998a,b) .
While the role of peripheral cannabinoid receptors nociceptive modulation is not as well understood as th of the central cannabinoid receptors, peripheral CB 2 rece tors have been reported to modulate inflammation. Palm toylethanolamide, a selective CB 2 cannabinoid recep
